Metastatic Melanoma Clinical Trials

29 studies are recruiting for metastatic melanoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

   This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (a…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Mayo Clinic Hospital in Arizona, Phoenix, Arizona

   Locations

   229 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05136196 on ClinicalTrials.gov

2. Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

   Background: Aldesleukin is used to treat metastatic or advanced melanoma and renal cell carcinoma. Pembrolizumab is used to treat many cancers including melanoma. Researchers want to see if these drugs can be used together to produce better results in people with these types of cancer. Objective: T…

   Stage

   Phase 2

   Ages

   18 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05155033 on ClinicalTrials.gov

3. A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

   Background: A type of drug called monoclonal antibody immune checkpoint inhibitors are often used in cancer treatment. These drugs help the body s immune system fight cancer by blocking proteins that cause cancer cells to grow. One of these drugs (atezolizumab) is approved to treat certain cancers.…

   Stage

   Phase 1

   Ages

   18 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06066138 on ClinicalTrials.gov

4. A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

   This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binimetinib may stop the growth of tumor cells by blocking some of…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Alabama at Birmingham Cancer Center, Birmingham, Alabama

   Locations

   331 in total

   Run by

   SWOG Cancer Research Network

   See if you can join NCT04511013 on ClinicalTrials.gov

5. A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma

   This is an open label study evaluating lifileucel (LN-144) in patients with metastatic uveal melanoma.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Westchester, Harrison, New York

   Locations

   2 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT05607095 on ClinicalTrials.gov

6. Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis

   This study is being done to see if combining HEPZATO KIT™ with nivolumab and relatlimab (Opdualag™) in patients with metastatic melanoma with liver metastasis is safe, tolerable, and will have a synergistic effect leading to improved clinical outcomes compared to the historic cohort of patients wit…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UW Hospital and Clinics, Madison, Wisconsin

   Run by

   University of Wisconsin, Madison

   See if you can join NCT07281924 on ClinicalTrials.gov

7. Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

   This phase II trial tests the combination of nivolumab and ipilimumab with sirolimus and prednisone for the treatment of skin (cutaneous) cancer that cannot be removed by surgery (unresectable) or that has spread from where it first started to other places in the body (metastatic) in kidney transpl…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UC San Diego Moores Cancer Center, La Jolla, California

   Locations

   26 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT05896839 on ClinicalTrials.gov

8. Cryoablation+Ipilimumab+Nivolumab in Melanoma

   The aim of this study is to find out whether the combination of two approved drugs, ipilimumab and nivolumab, in combination with cryoablation are safe and effective for participants who have an unresectable melanoma that is resistant, or is growing, after receiving immunotherapy with a PD-1 inhibi…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Massachusetts General Hospital Cancer Center, Boston, Massachusetts

   Run by

   Massachusetts General Hospital

   See if you can join NCT05779423 on ClinicalTrials.gov

9. ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab

   The purpose of this study is to investigate the use of ctDNA measurements to guide first-lien therapy choice for patients with advanced or metastatic melanoma. Primary endpoints include progression-free survival. Secondary study endpoints include objective response rate and incidence and severity o…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   NYU Langone Health, New York, New York

   Run by

   NYU Langone Health

   See if you can join NCT07504796 on ClinicalTrials.gov

10. Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

    This phase I/II trial tests the safety and tolerability of an experimental personalized vaccine when given by itself and with pembrolizumab in treating patients with solid tumor cancers that have spread to other places in the body (advanced). The experimental vaccine is designed target certain prot…

    Stage

    Phase 1

    Ages

    16 and older

    Site

    Mayo Clinic in Florida, Jacksonville, Florida

    Run by

    Mayo Clinic

    See if you can join NCT05269381 on ClinicalTrials.gov

11. Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors

    This is a Phase 1 open-label, study designed to characterize the safety, tolerability, and preliminary anti-tumor activity of memory-like natural killer cells (ML NK) in combination with nivolumab and relatlimab in subjects with advanced and/or metastatic melanoma. There will be two arms to test th…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Washington University School of Medicine, St Louis, Missouri

    Run by

    Washington University School of Medicine

    See if you can join NCT05629546 on ClinicalTrials.gov

12. Safety and Efficacy of OBX-115 in Advanced Solid Tumors

    This is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The Angeles Clinic and Research Institute (Melanoma), Los Angeles, California

    Locations

    10 in total

    Run by

    Obsidian Therapeutics, Inc.

    See if you can join NCT06060613 on ClinicalTrials.gov

13. Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma

    This phase I trial investigates the effects of influenza vaccine in treating patients with stage I-IV melanoma. While intramuscular administration of influenza vaccine provides immunization against the influenza virus, giving influenza vaccine directly into the tumor (intralesional) may decrease th…

    Stage

    Phase 1

    Ages

    18 to 99

    Site

    Ohio State University Comprehensive Cancer Center, Columbus, Ohio

    Run by

    Carlo Contreras

    See if you can join NCT04697576 on ClinicalTrials.gov

14. Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

    This is a Phase 3, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of lifileucel in combination with pembrolizumab compared with pembrolizumab alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to…

    Stage

    Phase 3

    Ages

    18 to 70

    Site

    University of Alabama at Birmingham: The Kirklin Clinic, Birmingham, Alabama

    Locations

    81 in total

    Run by

    Iovance Biotherapeutics, Inc.

    See if you can join NCT05727904 on ClinicalTrials.gov

15. Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types

    This study explores the role of T cells in monitoring disease status and response during anti-PD-1/PD-L1 treatment in patients with melanoma, lung and other cancer types. Measuring levels of specific targets such as Bim and soluble PD-L1 during therapy may help track treatment resistance and clinic…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Mayo Clinic in Rochester, Rochester, Minnesota

    Run by

    Mayo Clinic

    See if you can join NCT06075524 on ClinicalTrials.gov

16. A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel

    A Phase 1/2, open-label study of a modified interleukin-2 fusion protein (IOV 3001) in participants with previously treated, unresectable or metastatic melanoma who will receive lifileucel.

    Stage

    Phase 1

    Ages

    18 to 70

    Site

    SCRI Oncology Partners- Denver, Denver, Colorado

    Locations

    5 in total

    Run by

    Iovance Biotherapeutics, Inc.

    See if you can join NCT06940739 on ClinicalTrials.gov

17. Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

    This phase IV trial is evaluating whether morning versus afternoon administration of standard of care immunotherapy impacts its effectiveness in treating patients with solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced…

    Stage

    Phase 4

    Ages

    18 and older

    Site

    OHSU Knight Cancer Institute, Portland, Oregon

    Run by

    OHSU Knight Cancer Institute

    See if you can join NCT07405086 on ClinicalTrials.gov

18. Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

    This phase II trial studies the effect of avapritinib in treating malignant solid tumors that have a genetic change (mutation) in CKIT or PDGFRA and have spread to nearby tissue or lymph nodes (locally advanced) or other places in the body (metastatic). Avapritinib may stop the growth of tumor cell…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    M D Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT04771520 on ClinicalTrials.gov

19. A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

    This is a study to investigate the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma or advanced non-small-cell lung cancer (NSCLC).

    Stage

    Phase 1

    Ages

    18 to 70

    Site

    The Angeles Clinic and Research Institute, Los Angeles, California

    Locations

    11 in total

    Run by

    Iovance Biotherapeutics, Inc.

    See if you can join NCT05361174 on ClinicalTrials.gov

20. Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain

    This phase I/II trial tests the safety, side effects, and best dose of universal donor UD TGFbetai natural killer (NK) cells, and whether UD TGFbetai NK cells with temozolomide works to shrink tumors in patients with stage IV melanoma that has spread to the brain (metastatic to the brain). NK cells…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Ohio State University Comprehensive Cancer Center, Columbus, Ohio

    Run by

    Kari Kendra

    See if you can join NCT05588453 on ClinicalTrials.gov

21. MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma

    In this first-in human, phase I/IIa study, the safety and efficacy of [212Pb]VMT01, an alpha-particle emitting therapeutic agent targeted to melanocortin sub-type 1 receptor (MC1R) is being evaluated as a monotherapy and in combination with nivolumab in subjects with unresectable and metastatic mel…

    Stage

    Phase 1

    Ages

    18 to 90

    Site

    University of California Irvine, Orange, California

    Locations

    13 in total

    Run by

    Perspective Therapeutics

    See if you can join NCT05655312 on ClinicalTrials.gov

22. IL-17 Blockade to Decrease irAEs (REPLAY)

    The primary objective of this study is to determine the safety and feasibility of administering an IL-17A (human IgG1κ) monoclonal antibody, (Secukinumab, Cosentyx®) to participants with metastatic melanoma who have previously received immune checkpoint inhibitor (ICI) therapy, experienced an immun…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Duke University Health System, Durham, North Carolina

    Run by

    Duke University

    See if you can join NCT07237594 on ClinicalTrials.gov

23. Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases

    This phase II trial studies the effects of binimetinib and encorafenib in treating patients with melanoma that has spread to the central nervous system (metastases). Binimetinib and encorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving binimet…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    M D Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT05026983 on ClinicalTrials.gov

24. Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial

    This trial compares cryoablation combined with stereotactic body radiation therapy to stereotactic body radiation therapy alone to see how well they work in treating patients with pain from cancer that has spread to the bones (bone metastases). Bone is a common site of metastasis in advanced cancer…

    Stage

    Not phased

    Ages

    18 and older

    Site

    M D Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT04693377 on ClinicalTrials.gov

25. Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

    This phase I trial studies the side effects and best dose of modified immune cells (IL13Ralpha2 CAR T cells) after a chemotherapy conditioning regimen for the treatment of patients with stage IIIC or IV melanoma or solid tumors that have spread to other places in the body (metastatic). The study ag…

    Stage

    Phase 1

    Ages

    18 to 75

    Site

    City of Hope, Duarte, California

    Locations

    3 in total

    Run by

    Anusha Kalbasi

    See if you can join NCT04119024 on ClinicalTrials.gov